SkyBridge Capital II LLC increased its stake in shares of Merck & Co. (NYSE:MRK) by 40.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 227,970 shares of the company’s stock after buying an additional 65,171 shares during the period. Merck & Co. comprises approximately 3.5% of SkyBridge Capital II LLC’s holdings, making the stock its 13th largest position. SkyBridge Capital II LLC’s holdings in Merck & Co. were worth $13,133,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the stock. Raymond James Trust N.A. boosted its position in Merck & Co. by 3.3% in the second quarter. Raymond James Trust N.A. now owns 337,745 shares of the company’s stock valued at $19,457,000 after buying an additional 10,865 shares in the last quarter. Emerald Acquisition Ltd. bought a new position in Merck & Co. during the second quarter valued at approximately $274,347,000. Nordea Investment Management AB boosted its position in Merck & Co. by 16.1% in the second quarter. Nordea Investment Management AB now owns 2,411,985 shares of the company’s stock valued at $138,954,000 after buying an additional 334,806 shares in the last quarter. Orbis Allan Gray Ltd bought a new position in Merck & Co. during the first quarter valued at approximately $239,761,000. Finally, Envestnet Asset Management Inc. boosted its position in Merck & Co. by 7.0% in the first quarter. Envestnet Asset Management Inc. now owns 1,107,242 shares of the company’s stock valued at $58,584,000 after buying an additional 72,808 shares in the last quarter. Institutional investors and hedge funds own 72.93% of the company’s stock.
Merck & Co. (NYSE:MRK) opened at 62.14 on Monday. The firm has a market cap of $171.83 billion, a price-to-earnings ratio of 34.09 and a beta of 0.68. The company has a 50-day moving average of $62.56 and a 200 day moving average of $58.70. Merck & Co. has a 52-week low of $47.97 and a 52-week high of $64.86.
Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Friday, July 29th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The company earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter last year, the firm posted $0.86 EPS. The company’s quarterly revenue was up .6% on a year-over-year basis. On average, equities research analysts anticipate that Merck & Co. will post $3.75 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 15th were issued a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a dividend yield of 2.96%. The ex-dividend date of this dividend was Tuesday, September 13th. Merck & Co.’s payout ratio is 101.10%.
MRK has been the topic of several research analyst reports. Bank of America Corp. upgraded shares of Merck & Co. from a “neutral” rating to a “buy” rating and boosted their price target for the company from $57.00 to $70.00 in a report on Thursday. Berenberg Bank reiterated a “hold” rating and issued a $62.00 price objective on shares of Merck & Co. in a report on Sunday, September 11th. Argus reiterated a “buy” rating and issued a $65.00 price objective on shares of Merck & Co. in a report on Wednesday, September 14th. Jefferies Group reiterated a “hold” rating and issued a $56.00 price objective (down from $57.00) on shares of Merck & Co. in a report on Monday, September 12th. Finally, Barclays PLC reiterated an “overweight” rating on shares of Merck & Co. in a report on Wednesday, October 12th. Twelve research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of €65.58 ($72.87).
In related news, EVP Clark Golestani sold 3,000 shares of Merck & Co. stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of €63.03 ($70.03), for a total transaction of €189,090.00 ($210,100.00). The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Kenneth C. Frazier sold 392,000 shares of Merck & Co. stock in a transaction dated Friday, August 5th. The stock was sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the sale, the chairman now directly owns 760,877 shares of the company’s stock, valued at approximately €47,029,807.37 ($52,255,341.52). The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.